Novartis, J&J offer backing to Atlas Genetics in £16.9m round
This article was originally published in Clinica
Executive Summary
An investor syndicate which includes healthcare giants Novartis and Johnson & Johnson has pumped £16.9m ($27.3m) in series B financing into Atlas Genetics, a UK company developing ultra-rapid, point-of-care tests for infectious diseases.